New hope for teens with severe hay fever: xolair shows promise
NCT ID NCT04648930
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested Xolair (omalizumab) in 50 teenagers aged 12 to 17 with severe seasonal allergic rhinitis (hay fever) that standard treatments couldn't control. Researchers tracked side effects and how much symptoms improved. The goal was to see if Xolair is safe and effective in this age group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Xolair (omalizumab)
What this could lead to
If successful, this could show that Xolair is a safe and effective option for teenagers with severe seasonal allergies that don't respond to usual treatments.
What could go wrong
This was a small, uncontrolled study with only 50 participants, so results may not apply to everyone. Side effects like injection reactions are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGIC RHINITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.